1 / 10

Best Cure of Allergy in Jaipur and Covid-19 treatment by Dr. Nishtha Singh

Best Cure of Allergy in Jaipur and Covid-19 treatment by Dr. Nishtha Singh

Download Presentation

Best Cure of Allergy in Jaipur and Covid-19 treatment by Dr. Nishtha Singh

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. FDA: You Can Use Chloroquine to Treat COVID-19; EU Regulators: Not Just Yet

  2. Updated :April 01. 2020 07:05 AM IST Healthcare • Indian government/ ICMR approves hydroxychloroquine (Dose 400mg BD –for 1 day followed by 200mg BD for 4 days) + azithromycin (500mg OD for 5 days) for critical COVID-19 patients

  3. Chemoprophylaxis • Recommended for 2 high risk groups • 1) Asymptomatic health care workers involved in treating confirmed or suspected COVID-19 patients • Dose: 400mg twice a day on Day1,followed by 400mg once weekly for next 7 weeks • 2) Asymptomatic household contacts of laboratory confirmed cases • Dose:400mg twice a day on Day1, followed by 400mg once weekly for next 3 weeks

  4. Chloroquine/Hydroxychloroquine Prevention of coronavirus disease (COVID-19) in the Healthcare setting; a Randomised, placebo-controlled Prophylaxis study (COPCOV)

  5. My take on the HCQS story - - • HCQS FOR TREATMENT • Considering the dire situation we are in with: • No other drugs options • No vaccine in sight, • Relatively good safety profile • IT MAY BE REASONABLE TO USE HCQS FOR SYMPTOMATIC PATIENTS HCQS FOR PROPHYLAXIS Data even more scanty ICMR recommended Dose of once a week seems neither here nor there INDIVIDUAL DECISION?

  6. Jak inhibitors/Baricitinib MOA- The receptors of novel coronavirus pneumonia (2019-nCoV), might be ACE2, which is a cell-surface protein widely existed on cells in the heart, kidney, blood vessels, especially alveolar epithelial cells. 2019-nCoV could invade and enter cells through endocytosis. One of the known regulators of endocytosis is the AP2-associated protein kinase 1 (AAK1). AAK1 inhibitors can interrupt the passage of the virus into cells and can be helpful in preventing virus infections. Baricitinib, a JAK inhibitor as well as an AAK1 inhibitor, was suggested a possible candidate for treatment of COVID-19, considering its relative safety and high: “Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19)

  7. The role of Convalescent plasma in treatment of SARS COVID 19

  8. Plasma Plasma cells collected from donors who have recovered from COVID-19. These cells contain antibodies that can help the body protect itself from coronavirus. Dose :- One unit of COVID-19 Convalescent Plasma of High Titer

  9. Convalescent plasma: background • 2014: Recommended as an empirical treatment during the Ebola outbreak • 2015: A protocol for treatment of MERS coronavirus was established • Also considered effective in other viral infection: SARS-CoV1, H5N1 avian influenza, and H1N1 influenza

More Related